Treatment with Octreotide in Patients with Well-Differentiated Neuroendocrine Tumors of the Ileum: Prognostic Stratification with Ga-68-DOTA-TATE Positron Emission Tomography

Biotherapies for GEP-NETs

(2013) Kjell Öberg   BEST PRACTICE & RESEARCH IN CLINICAL GASTROENTEROLOGY

Comparison of 68Ga-DOTANOC and 68Ga-DOTATATE PET/CT Within Patients with Gastroenteropancreatic Neuroendocrine Tumors

(2013) D. Wild et al.   JOURNAL OF NUCLEAR MEDICINE

Quantification in68Ga-DOTA(0)-Phe(1)-Tyr(3)-Octreotide Positron Emission Tomography/Computed Tomography: Can We Be Impartial about Partial Volume Effects?

(2013) Juri Ruf et al.   NEUROENDOCRINOLOGY

Comparison of Ga-68 DOTA-TATE and Ga-68 DOTA-LAN PET/CT imaging in the same patient group with neuroendocrine tumours

(2013) Emre Demirci et al.   NUCLEAR MEDICINE COMMUNICATIONS

Semiquantitative Analysis and Characterization of Physiological Biodistribution of 68Ga-DOTA-TATE PET/CT

(2012) Jolanta Kunikowska et al.   CLINICAL NUCLEAR MEDICINE

Feasibility and availability of 68Ga-labelled peptides

(2012) Clemens Decristoforo et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Treatment with Octreotide Does Not Reduce Tumor Uptake of 68Ga-DOTATATE as Measured by PET/CT in Patients with Neuroendocrine Tumors

(2011) A. R. Haug et al.   JOURNAL OF NUCLEAR MEDICINE

The Impact of 68Ga-DOTATOC Positron Emission Tomography/Computed Tomography on the Multimodal Management of Patients With Neuroendocrine Tumors

(2010) Andrea Frilling et al.   ANNALS OF SURGERY

Standardized Uptake Values of 68Ga-DOTANOC PET: A Promising Prognostic Tool in Neuroendocrine Tumors

(2010) D. Campana et al.   JOURNAL OF NUCLEAR MEDICINE

68Ga-DOTANOC PET/CT Clinical Impact in Patients with Neuroendocrine Tumors

(2010) V. Ambrosini et al.   JOURNAL OF NUCLEAR MEDICINE

The Role of 68Ga-DOTATATE PET in Patients with Neuroendocrine Tumors and Negative or Equivocal Findings on 111In-DTPA-Octreotide Scintigraphy

(2010) R. Srirajaskanthan et al.   JOURNAL OF NUCLEAR MEDICINE

68Ga-DOTA-NOC PET/CT Imaging of Neuroendocrine Tumors: Comparison with 111In-DTPA-Octreotide (OctreoScan®)

(2010) Yodphat Krausz et al.   MOLECULAR IMAGING AND BIOLOGY

Quantifizierung der Somatostatinrezeptorexpression neuroendokriner Tumoren mit der 68Ga-DOTATATE-PET/CT

(2010) A.R. Haug et al.   RADIOLOGE

Immunohistochemical expression of somatostatin receptors in digestive endocrine tumours

(2009) V. Zamora et al.   DIGESTIVE AND LIVER DISEASE

Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients With Metastatic Neuroendocrine Midgut Tumors: A Report From the PROMID Study Group

(2009) Anja Rinke et al.   JOURNAL OF CLINICAL ONCOLOGY

Bone Metastases in Patients with Neuroendocrine Tumor: 68Ga-DOTA-Tyr3-Octreotide PET in Comparison to CT and Bone Scintigraphy

(2009) D. Putzer et al.   JOURNAL OF NUCLEAR MEDICINE

From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors

(2009) R. L. Wahl et al.   JOURNAL OF NUCLEAR MEDICINE

Functional imaging of neuroendocrine tumors with combined PET/CT using68Ga-DOTATATE (DOTA-DPhe1,Tyr3-octreotate) and18F-FDG

(2008) Irfan Kayani et al.   CANCER

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER

Comparison between 68Ga-DOTA-NOC and 18F-DOPA PET for the detection of gastro-entero-pancreatic and lung neuro-endocrine tumours

(2008) Valentina Ambrosini et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Correlation of immunohistopathological expression of somatostatin receptor 2 with standardised uptake values in 68Ga-DOTATOC PET/CT

(2008) Matthias Miederer et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Indium-111–Pentetreotide Scintigraphy and Somatostatin Receptor Subtype 2 Expression: New Prognostic Factors for Malignant Well-Differentiated Endocrine Tumors

(2008) Amani Asnacios et al.   JOURNAL OF CLINICAL ONCOLOGY